Drug Profile
Research programme: talin protease inhibitor - Kaytee Bio
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Kaytee Bio
- Class Antirheumatics
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Rheumatoid-arthritis in Japan
- 26 Jul 2016 Early research in Rheumatoid arthritis in Japan (unspecified route)